Trump Governance’s Plan to Lower Weight Loss Drug Costs Faces hurdles Beyond Price
Table of Contents
The Trump administration announced a landmark agreement on November 6, 2025, to substantially reduce the cost of popular weight loss drugs, possibly offering relief to millions of Americans struggling with obesity. However, experts caution that affordability is only one piece of a complex puzzle, and lasting change will require broader policy interventions.
For decades, effective treatments for obesity have been underutilized, a frustration echoed by clinicians on the front lines of the public health crisis. These newer medications, initially developed for Type 2 diabetes, work by mimicking a natural hormone – glucagon-like peptide-1 (GLP-1) – which regulates blood sugar and suppresses appetite. “By making GLP-1 drugs more accessible, this agreement represents a notable advance in addressing obesity,” one expert stated, “but it’s not a panacea.”
currently, treatment approaches include lifestyle modifications – diet and exercise – which can yield around 5% weight loss in the same timeframe, and metabolic and bariatric surgery, capable of producing a 30% weight loss after about 18 months. The optimal treatment strategy varies depending on individual circumstances and should be determined in consultation with a healthcare provider,yet,according to clinicians,referrals to these therapies remain surprisingly low.
Addressing the Affordability Crisis
A November 2025 poll from the Kaiser Family Foundation revealed that only 1 in 8 American adults have tried a GLP-1 medication, a figure that seems low considering the prevalence of obesity. A major barrier to access has been cost. Currently, GLP-1 drugs can exceed $1,000 per month for those without insurance coverage, and many insurance plans offer limited or no benefits.
The federal government’s deal with Eli Lilly and Novo Nordisk aims to dismantle this barrier.Starting in early 2026, select GLP-1 drugs covered under the agreement will be available for $350 per month or less through a government-launched online marketplace. Some medications could be priced as low as $150. Furthermore, the agreement includes reduced costs for Medicare and Medicaid, with certain Medicare patients eligible for a $50 co-pay.
However, even these reduced prices may remain prohibitive for many. “Paying even $150 a month remains a budget buster for a significant portion of the population,” one analyst noted, especially for individuals from lower socioeconomic backgrounds who often face higher rates of obesity and co-occurring health conditions. Crucially, these medications are often needed long-term; research indicates that individuals typically regain weight upon discontinuation, and lifestyle changes alone are often insufficient to maintain weight loss.
Beyond Cost: A Multifaceted Approach is Needed
While the reduced pricing is a crucial first step, experts emphasize that it’s insufficient on its own. The environments in which people live often make healthy choices difficult, necessitating broader policy changes. Unlike many other countries with national obesity prevention and treatment plans, the U.S. relies on a state-by-state approach, resulting in fragmented and often inadequate policies.
More extensive legislation targeting obesity prevention is needed. Emerging research highlights the role of ultraprocessed foods in promoting weight gain and potentially increasing the risk of diseases like colorectal cancer. Legislators could consider regulating these foods by limiting harmful ingredients, restricting marketing, or reducing their presence in school meals.
Moreover, enhancing nutrition education for medical students and healthcare providers could equip the next generation of clinicians to better guide patients toward healthier choices. . These and other policy shifts will be critical in tackling the obesity epidemic and improving the health of all Americans.
This article is republished from The Conversation under a Creative Commons license.Read the original article.
Citation: Making GLP-1 weight loss drugs cheaper isn’t enough to address America’s obesity problem. Here’s why (2025, November 22) retrieved 22 November 2025 from https://medicalxpress.com/news/2025-11-glp-weight-loss-drugs-cheaper.html. This document is subject to copyright. Apart from any fair dealing to private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
